APA (7th ed.) Citation

Kong, L., Peng, L., Yang, X., Ma, Q., Zhang, L., Liu, X., . . . Meng, F. Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Kong, Lingping, Lina Peng, Xue Yang, Qing Ma, Linlin Zhang, Xia Liu, Diansheng Zhong, and Fanlu Meng. Aumolertinib Plus Bevacizumab for Untreated Advanced NSCLC with EGFR Sensitive Mutation. Frontiers Media S.A.

MLA (9th ed.) Citation

Kong, Lingping, et al. Aumolertinib Plus Bevacizumab for Untreated Advanced NSCLC with EGFR Sensitive Mutation. Frontiers Media S.A.